{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:07:13Z","timestamp":1789175233357,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.radonc.2025.111027","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T11:52:27Z","timestamp":1752580347000},"page":"111027","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["NTCP models based on CT-guided online adaptive SBRT for abdominal lymph node oligometastases"],"prefix":"10.1016","volume":"210","author":[{"given":"Lucy A.","family":"van Werkhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike T.W.","family":"Milder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mischa S.","family":"Hoogeman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Remi A.","family":"Nout","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost J.","family":"Nuyttens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2025.111027_b0005","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nrclinonc.2014.96","article-title":"The oligometastatic state - separating truth from wishful thinking","volume":"11","author":"Palma","year":"2014","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0010","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of Oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0020","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12032-022-01788-8","article-title":"A critical review on oligometastatic disease: a radiation oncologist's perspective","volume":"39","author":"Pacifico","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0025","doi-asserted-by":"crossref","first-page":"5897","DOI":"10.1002\/cam4.4139","article-title":"Clinical outcomes of stereotactic magnetic resonance image-guided adaptive radiotherapy for primary and metastatic tumors in the abdomen and pelvis","volume":"10","author":"Yoon","year":"2021","journal-title":"Cancer Med."},{"key":"10.1016\/j.radonc.2025.111027_b0030","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/jso.25361","article-title":"Outcomes after hypofractionated stereotactic radiotherapy for colorectal cancer oligometastases","volume":"119","author":"Yu","year":"2019","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0035","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/j.prro.2021.03.005","article-title":"Organ at risk dose constraints in SABR: a systematic review of active clinical trials","volume":"11","author":"Gerhard","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0040","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM task group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med. Phys."},{"key":"10.1016\/j.radonc.2025.111027_b0045","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.radonc.2019.01.030","article-title":"Modeling daily changes in organ-at-risk anatomy in a cohort of pancreatic cancer patients","volume":"134","author":"Magallon-Baro","year":"2019","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0050","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clon.2017.09.007","article-title":"UK consensus on Normal tissue dose constraints for stereotactic radiotherapy","volume":"30","author":"Hanna","year":"2018","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"10.1016\/j.radonc.2025.111027_b0055","doi-asserted-by":"crossref","first-page":"46","DOI":"10.5603\/RPOR.a2022.0007","article-title":"Stereotactic radiotherapy for oligometastases in the lymph nodes","volume":"27","author":"Pasqualetti","year":"2022","journal-title":"Rep Pract Oncol Radiother"},{"key":"10.1016\/j.radonc.2025.111027_b0060","doi-asserted-by":"crossref","first-page":"822","DOI":"10.2340\/1651-226X.2024.40681","article-title":"Stereotactic body radiation therapy on abdominal-pelvic lymph node oligometastases: a systematic review on toxicity","volume":"63","author":"Van Werkhoven","year":"2024","journal-title":"Acta Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0065","article-title":"Results of a single arm phase II clinical trial: online-adaptive stereotactic body radiotherapy of abdominal-pelvic oligometastases","author":"Van Werkhoven","year":"2024","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.111027_b0070","doi-asserted-by":"crossref","first-page":"4816","DOI":"10.1002\/mp.12432","article-title":"CyberKnife with integrated CT-on-rails: system description and first clinical application for pancreas SBRT","volume":"44","author":"Papalazarou","year":"2017","journal-title":"Med. Phys."},{"key":"10.1016\/j.radonc.2025.111027_b0075","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2009.04.048","article-title":"Predicting grade 3 acute diarrhea during radiation therapy for rectal cancer using a cutoff-dose logistic regression normal tissue complication probability model","volume":"77","author":"Robertson","year":"2010","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.111027_b0080","unstructured":"Agresti AF, B. Statistical Methods for Social Sciences. 4th ed. 2009."},{"key":"10.1016\/j.radonc.2025.111027_b0085","article-title":"Dosimetric predictors of acute and late gastrointestinal toxicities in stereotactic online adaptive magnetic resonance-guided radiotherapy (SMART) for locally advanced pancreatic adenocarcinoma","volume":"200","author":"D'Souza","year":"2024","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s10585-020-10047-x","article-title":"Phase II trial of high dose stereotactic body radiation therapy for lymph node oligometastases","volume":"37","author":"Franzese","year":"2020","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.radonc.2025.111027_b0095","article-title":"1.5 T MR-Guided daily Adapted SBRT on lymph node Oligometastases from","author":"Nicosia","year":"2022","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.radonc.2025.111027_b0100","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00066-018-1395-y","article-title":"Patient- versus physician-reported outcomes in prostate cancer patients receiving hypofractionated radiotherapy within a randomized controlled trial","volume":"195","author":"Rammant","year":"2019","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.radonc.2025.111027_b0105","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1200\/JCO.2014.57.9334","article-title":"Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials","volume":"33","author":"Di Maio","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.radonc.2025.111027_b0110","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1002\/cncr.10248","article-title":"The association of treatment-related symptoms with quality-of-life outcomes for localized prostate carcinoma patients","volume":"94","author":"Bacon","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2025.111027_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2025.03.020","article-title":"CT-guided online adaptive SBRT for lymph node oligometastases: impact on dose to target and organs at risk","author":"van Werkhoven","year":"2025","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.radonc.2025.111027_b0120","doi-asserted-by":"crossref","first-page":"185","DOI":"10.3748\/wjg.v19.i2.185","article-title":"Gastrointestinal radiation injury: symptoms, risk factors and mechanisms","volume":"19","author":"Shadad","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.radonc.2025.111027_b0125","doi-asserted-by":"crossref","first-page":"e121","DOI":"10.1016\/S1470-2045(22)00752-5","article-title":"Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium","volume":"24","author":"Kroeze","year":"2023","journal-title":"Lancet Oncol."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045311?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814025045311?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:26:53Z","timestamp":1789172813000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814025045311"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":25,"alternative-id":["S0167814025045311"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111027","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NTCP models based on CT-guided online adaptive SBRT for abdominal lymph node oligometastases","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2025.111027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"111027"}}